Want to see BYSI full AI Analyst Report?
BYSI Stock Chart & Stats
$0.66
$0.05(4.46%)
At close: 4:00 PM EDT
$0.66
$0.05(4.46%)
Day’s Range― - ―
52-Week Range$0.42 - $2.44
Previous Close$1.17
Volume9.77K
Average Volume (3M)405.29K
Market Cap
$21.57M
Enterprise Value$65.14M
Total Cash (Recent Filing)$6.53M
Total Debt (Recent Filing)$171.00K
Price to Earnings (P/E)―
Beta-0.20
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,119,820
10 Day Avg. Volume42,141
30 Day Avg. Volume405,293
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)-2.05
Price to Sales (P/S)0.00
P/FCF Ratio-3.28
Enterprise Value/Market Cap3.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.71K
Enterprise Value/Ebitda-8.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Capital-efficient CollaborationThe China transaction shifts a substantial portion of Phase 3 funding responsibility to Biolin while preserving BeyondSpring’s ability to use the resulting data outside Greater China. This can reduce near-term cash demands and improve development efficiency without surrendering global commercialization rights.
Regulatory PathwayFast Track designation may support more frequent FDA interaction and potentially expedite review for the targeted NSCLC indication. Although it does not establish approval or commercial success, it strengthens the regulatory development pathway and may help focus resources around a defined registration strategy.
Narrowing LossesThe substantial reduction in annual net losses compared with 2020–2021 indicates progress in controlling the company’s expense burden. While profitability remains distant, lower absolute losses could extend the value of available funding and make future development spending more manageable.
Bears Say
Persistent Cash BurnRecurring negative operating and free cash flow means the company cannot currently fund its activities from internally generated cash. Continued clinical development therefore depends on external financing or remaining liquidity, creating durable funding pressure and potential dilution or program constraints.
Negative EquityNegative shareholder equity and a sharply smaller asset base indicate limited balance-sheet resilience despite modest dollar debt. This weak capital position reduces financial flexibility, makes additional funding more consequential, and leaves the company less able to absorb setbacks in development or regulatory execution.
Nasdaq Compliance RiskThe market-value deficiency creates a continuing listing risk that could affect access to public capital and investor participation if compliance is not restored. The company has a defined grace period, but Nasdaq stated that there is no certainty it will satisfy the requirement or retain its listing.
Beyondspring News
BYSI FAQ
What was Beyondspring Inc’s price range in the past 12 months?
Beyondspring Inc lowest stock price was $0.42 and its highest was $2.44 in the past 12 months.
What is Beyondspring Inc’s market cap?
Beyondspring Inc’s market cap is $21.57M.
When is Beyondspring Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Beyondspring Inc’s earnings last quarter?
Currently, no data Available
Is Beyondspring Inc overvalued?
According to Wall Street analysts Beyondspring Inc’s price is currently Overvalued.
Does Beyondspring Inc pay dividends?
Beyondspring Inc does not currently pay dividends.
What is Beyondspring Inc’s EPS estimate?
Beyondspring Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beyondspring Inc have?
Beyondspring Inc has 41,119,820 shares outstanding.
What happened to Beyondspring Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Beyondspring Inc?
Currently, no hedge funds are holding shares in BYSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Beyondspring Inc
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
Technical Analysis
Ownership Overview
1.16% Insiders
2.23% Mutual Funds
0.03% Other Institutional Investors
94.65% Public Companies and
Individual Investors